Neoplastic meningitis

Current Treatment Options in Oncology

Volumn 2, Issue 6, 2001, Pages 517-527

  Kim, Lyndon ^a   Glantz, Michael J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Contraindication Hypersensitivity; Intrathecal Chemotherapy; Intrathecal Methotrexate; Leptomeningeal Metastasis; Main Drug Interaction

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD; BRAIN TUMOR; CANCER INVASION; CARCINOMA; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; GLIOMA; HUMAN; MENINGITIS; METASTASIS; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; REVIEW; RISK FACTOR; SKULL IRRADIATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DIAGNOSTIC IMAGING; EPIDEMIOLOGIC METHODS; GLIOMA; HUMANS; MENINGITIS; NEOPLASM INVASIVENESS; PALLIATIVE CARE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0035755195     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0073-x     Document Type: Article

References (63)

1. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759–772. Classic clinical and laboratory description of this disease; still the best overview of solid tumor neoplastic meningitis available. DOI: 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7
2. Yap HY, Yap BS, Tashima CK, et al.: Meningeal carcinomatosis in breast cancer. Cancer 1978, 42:283–286. DOI: 10.1002/1097-0142(197807)42:1<283::AID-CNCR2820420142>3.0.CO;2-#
3. Chamberlain MC: Carcinomatous meningitis. Arch Neurol 1997, 54:16–17.
4. Jayson GC, Howell A: Carcinomatous meningitis in solid tumors. Ann Oncol 1996, 7:773–786.
5. Balm M, Hammock J: Leptomeningeal carcinomatosis. Arch Neurol 1996, 53:626–632.
6. Grossman SA, Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev 1999, 25:103–119. Extremely thoughtful, up-to-date, detailed, and meticulously referenced general review article. DOI: 10.1053/ctrv.1999.0119
7. DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastases. J Neurooncol 1998, 38:245–252. DOI: 10.1023/A:1005956925637
8. Greenlee RJ, Hill-Harmon MB, Murry J, Thun M: Cancer Statistics 2001. CA Cancer J Clin 2001, 51:15–36.
9. Kaplan JG, DeSouza TG, Farkash A, et al.: Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas, and leukemias. J Neurooncol 1990, 9:225–229. DOI: 10.1007/BF02341153
10. Posner JB: Neurologic Complications of Cancer. Philadelphia: F.A. Davis 1995:143–171.
11. Shapiro WR, Posner JB, Ushio Y, et al.: Treatment of meningeal neoplasms. Cancer Treat Rep 1977, 61:733–743.
12. Malkin MG, Posner JB: Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases. Eur J Cancer Clin Oncol 1987, 23:1–4. DOI: 10.1016/0277-5379(87)90410-X
13. Aroney RS, Dalley DN, Chan WK, et al.: Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981, 71:26–32. DOI: 10.1016/0002-9343(81)90254-0
14. Freilich RJ, Seidman AD, DeAngelis LM: Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995, 76:232–236. DOI: 10.1002/1097-0142(19950715)76:2<232::AID-CNCR2820760212>3.0.CO;2-0
15. Fishman RA: Cerebrospinal fluid in diseases of the nervous system, edn. 2. Philadelphia: W.B. Saunders; 1992:7–40. The ultimate reference for any detail regarding the cerebrospinal fluid; justly renowned.
16. Norris LK, Grossman SA, Olivi A: Neoplastic meningitis following surgical resection of isolated cerebellar metastases: a potentially preventable complication. J Neurooncol 1997, 32:215–223. DOI: 10.1023/A:1005723801479
17. Grossman SA, Trump DL, Chen DCP, et al.: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis: an evaluation using 111indium DTPA ventriculography. Am J Med 1982, 73:641–647. DOI: 10.1016/0002-9343(82)90404-1
18. Chamberlain MC, Corey-Bloom J: Leptomeningeal metastases: 111indium DTPA CSF flow studies. Neurol 1991, 41:1765–1769.
19. Glantz MJ, Hall WA, Cole BF, et al.: Diagnosis, management of, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75:2919–2931. Review of the technique, results, and clinical importance of assessing CSF flow; abundant illustrations of CSF flow studies that reflect normal and abnormal results. DOI: 10.1002/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9
20. Roelcke U, Leenders KL: PET in neuro-oncology. J Cancer Res Clin Oncol 2001, 127:2–8. DOI: 10.1007/s004320000158
21. Glantz MJ, Cole BF, Glantz LK, et al.: Cerebrospinal fluid cytology in patients with cancer: how to minimize false negative results. Cancer 1998, 82:733–739. Clinical study and review that describes the optimum techniques (volume, site, processing, number of samplings) for evaluating CSF cytology. DOI: 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z
22. Grossman SA, Finkelstein DM, Ruckdeschchel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993, 11:561–569. One of only four randomized clinical trials in this disease. This well-written work contains valuable information on the disease and treatment.
23. Hitchins RN, Bell DR, Woods RL, Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. Oncol 1987, 5:1655–1662. One of only four randomized clinical trials in this disease. Contains important clinical information.
24. Glantz MJ, Chamberlain MC, Walters BC: Diagnosis and outcome measures in trials for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus 1998, 4:1–7. DOI: 10.3171/foc.1998.4.6.7
25. Chamberlain MC: Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998, 50:1173–1175. Excellent, concise, recent clinical series and review of the role of biochemical markers in the diagnosis of neoplastic meningitis.
26. Schold SC, Wasserstrom WR, Fleisher M, et al.: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 1980, 8:597–604. DOI: 10.1002/ana.410080609
27. Stockhammer G, Poewve W, Burgstaller S, et al.: Vascular endothelial growth factor in CSF. A biological marker of carcinomatous meningitis. Neurology 2000, 54:1670–1676.
28. van Zanten AP, Twijnstra A, Ongerboer de Visser BW, et al.: Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991, 54:119–123.
29. Chamberlain MC: Leptomeningeal metastases. In Handbook of Clinical Neurology. Edited by Vecht CHJ. Amsterdam, the Netherlands: Elsevier Science BV; 1997:25:151–165.
30. Bigner SH: Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 1992, 51:235–245.
31. Rhodes CH, Glantz MJ, Glantz L, et al.: A comparison of PCR examination of CSF and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996, 77:543–548. DOI: 10.1002/(SICI)1097-0142(19960201)77:3<543::AID-CNCR17>3.0.CO;2-4
32. Friedberg MH, Glantz MJ, Klempner MS, et al.: Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases and carcinomatous meningitis. Cancer 1998, 82:923–930. DOI: 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2
33. Kim L, Glantz MJ, Callanan H, et al.: Diagnostic utility and potential therapeutic applications of inter-alpha trypsin inhibitor (ITI) in the cerebrospinal fluid of patients with primary and metastatic central nervous system cancer [abstract]. Pro Am Soc Clin Oncol 2000, 19:165a.
34. Katopodis N, Glantz M, Kim L, et al.: Lipid associated sialoprotien in the cerebrospinal fluid: association with brain malignancies. Cancer 2001, 92:856–862. DOI: 10.1002/1097-0142(20010815)92:4<856::AID-CNCR1393>3.0.CO;2-9
35. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38:51–57. DOI: 10.1002/ana.410380111
36. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ: The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999, 246:810–814. DOI: 10.1007/s004150050459
37. Grossman SA, Spence A: Management of leptomeningeal metastases: National Comprehensive Cancer Network guidelines. Oncology 1999, 13:144–152. Superb review and treatment algorithm for neoplastic meningitis.
38. Glantz MJ, LaFollette S, Jaeckle KA, et al.: A randomized trial of a slow-release formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110–3116. One of only four randomized clinical trials regarding this disease that focuses on lymphomatous meiningitis only.
39. Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394–3402. The most recent of only four randomized clinical trials regarding this disease; useful information regarding risk factors, treatment, and outcomes is provided.
40. Grossman SA, Reinhard CS, Loats HL: The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol 1989, 7:319–328. DOI: 10.1007/BF02147089
41. Burch PA, Grossman SA, Reinhard CS: Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. J Natl Cancer Inst 1988, 5:1211–1216. DOI: 10.1093/jnci/80.15.1211
42. Larson SM, Shcall Gl, Di Chiro G: The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med 1971, 12:555–557.
43. Shapiro WR, Young DF, Metha BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293:161–166. DOI: 10.1056/NEJM197507242930402
44. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44:1463–1469.
45. Kim S, Chatelut E, Kim JC, et al.: Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993, 11:2186–2193.
46. Glantz MJ, Cole BF, Recht L, et al.: High dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 1998, 16:1561–1567.
47. Chamberlain MC: A phase 2 trial of intra-CSF alpha interferon in the treatment of neoplastic meningitis. abstract AAN 2001, 56:(suppl):3:A476 S64.002.
48. Schulz H, Pels H, Rehwald U, et al.: Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with the anti-CD-20 antibody IDECC2B8 abstract AAN 2001, 56:(suppl):3:A411 P06.030.
49. Coakham HB, Kemshead JT: Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 1998, 38:225–232. DOI: 10.1023/A:1005996606073
50. Brown MT, Coleman RE, Friedman AH, et al.: Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996, 2:963–972.
51. Kamen BA, Holcenberg JS, Sieger SE: AziridinylbenzoquinoneAZQ) treatment of central nervous system leukemia: Letter to the editor. Cancer Treat Rep 1982, 66:2105–2106.
52. Champagne MA, Sislver HKB: Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma. J Natl Cancer Inst 1992, 84:1203–1204. DOI: 10.1093/jnci/84.15.1203
53. Huang T, Howng SL: Intrathecal ACNU against experimental leptomeningeal tumors. Kaosiung J Med Sci 1997, 13:626–630.
54. Balis FM, Lester C, Poplack DG: Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 1986, 46:169–174.
55. Friedman HS, Archer GE, Mc Lendon Re, et al.: Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Res 1994, 54:4710–4714.
56. Kochi M, Kuratsu J, Mihara Y, et al.: Neurotoxicity and pharmacokinetics of ventricularlumbar perfusion of methyl -6[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in dogs. J neurooncol 1994, 19:239–244. DOI: 10.1007/BF01053277
57. Blaney S, Cole D, Godwin K, et al.: Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995, 36:121–124.
58. Friedman HS, Petros W, Rich JN, et al.: Phase I trial of intrathecal Spartaject busulfan for patients with neoplastic meningitis [abstract]. Proc Am Soc Clin Oncol 2001, 20:57a.
59. Bruntsch U, Groos G, Hiller TA, et al.: Phase I study of mafosfamide-cyclohexlyamine (ASTA-Z-7557, NSC 345842) and limited Phase-I data on mafosfamidelysine. Invest New Drugs 1985, 3:293–296. DOI: 10.1007/BF00179434
60. Mitchell MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 1989, 7:1701–1709.
61. Samlowski WE, Park KJ, Galinski RE, et al.: Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: Sequential evaluation of intracranial pressure, cerebrospinal fluid cytology and cytokine induction. J Immunother 1993, 13:49–54. DOI: 10.1097/00002371-199301000-00007
62. Doge H, Hiscs R: Intrathecal therapy with 198Au-Colloid for meningosis prophylaxis. Eur J Nucl Med 1984, 9:125–128. DOI: 10.1007/BF00253514
63. Vincent AJ, Esandi MD, van Someran G, et al.: Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene. J Neurosurg 1996, 85:648–654. DOI: 10.3171/jns.1996.85.4.0648